After Vaccine Recalculation, AstraZeneca Looks To Move On But Likely Faces Extra US FDA Scrutiny
Results for AstraZeneca’s COVID shot edge down to 76% after data and safety monitoring board raised alarm about outdated figures.
You may also be interested in...
AZ Vaccine Safety: Germany Introduces Age Restrictions, But EMA Says Rare Blood Clot Link Still Unproven
The European Medicines Agency will reach its scientific conclusion next week, but countries are already moving to restrict use of the vaccine.
AstraZeneca Vaccine’s ‘Big Gap’: DSMB Questions Results Released By Firm In Latest Controversy
‘Harsh note’ from Data Safety and Monitoring Board follows AstraZeneca press release that contained incomplete information about the Phase III US trial for its COVID vaccine. It remains to be seen how the company will fix this ‘unforced error’ and weather the latest threat to public trust.
Investors Take Flight After Bluebird Bio’s Sickle Cell Delay
Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.